Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,026 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.
Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Yamamoto K; Iguratimod-Clinical Study Group. Hara M, et al. Among authors: katayama k. Mod Rheumatol. 2014 May;24(3):410-8. doi: 10.3109/14397595.2013.843756. Epub 2013 Nov 7. Mod Rheumatol. 2014. PMID: 24252050 Clinical Trial.
Tacrolimus-induced pulmonary injury in rheumatoid arthritis patients.
Koike R, Tanaka M, Komano Y, Sakai F, Sugiyama H, Nanki T, Ide H, Jodo S, Katayama K, Matsushima H, Miwa Y, Morita K, Nakashima H, Nakamura H, Natsumeda M, Sato Y, Semba S, Tateishi M, Miyasaka N, Harigai M. Koike R, et al. Among authors: katayama k. Pulm Pharmacol Ther. 2011 Aug;24(4):401-6. doi: 10.1016/j.pupt.2011.01.016. Epub 2011 Feb 21. Pulm Pharmacol Ther. 2011. PMID: 21300166
Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial.
Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi T, Hara M; Iguratimod-Clinical Study Group. Ishiguro N, et al. Among authors: katayama k. Mod Rheumatol. 2013 May;23(3):430-9. doi: 10.1007/s10165-012-0724-8. Epub 2012 Jul 26. Mod Rheumatol. 2013. PMID: 22833377 Clinical Trial.
One-year maintenance with routine assessment of patient index data 3-based remission may inhibit radiographic progression in patients with rheumatoid arthritis treated with routine clinical therapy: A retrospective comparison of radiographic outcome and its prognostic factors between maintained remissions with patient-reported outcome index and physician-oriented disease activity indices.
Katayama K, Okubo T, Sato T, Kamiya K, Fukai R, Abe S, Ito H, Makino Y, Kamishima T. Katayama K, et al. Mod Rheumatol. 2016 Nov;26(6):817-827. doi: 10.3109/14397595.2016.1158766. Epub 2016 Mar 22. Mod Rheumatol. 2016. PMID: 26915909
2,026 results